Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02558400 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

718

Enrollment

INDUSTRY

Sponsor class

Conditions

Open-angle Glaucoma
Ocular Hypertension

Interventions

DRUG: PG324 Ophthalmic Solution 0.02%/0.005%
DRUG: Netarsudil (AR-13324) Ophthalmic Solution 0.02%
DRUG: Latanoprost Ophthalmic Solution 0.005%

Sponsor

Aerie Pharmaceuticals